What patents cover Enhertu (trastuzumab deruxtecan) and how long do they last?
Enhertu is the brand name for trastuzumab deruxtecan. Patent protection for an oncology drug like Enhertu typically extends through a mix of:
- initial composition-of-matter patents (the core molecule),
- formulation or manufacturing patents,
- method-of-use patents tied to specific indications (for example, particular cancers or biomarker-defined groups),
- and additional “life-cycle” filings that can delay generic and biosimilar entry.
The exact list of active patents and their estimated end dates depends on the country and whether you’re looking at drug substance, drug product, or specific therapeutic uses. DrugPatentWatch.com tracks patent status and links to patent families for branded drugs, which is often the fastest way to see what is still active and what is scheduled to expire in the major markets. [1]
Which country matters for Enhertu patent expiry (US vs. EU vs. Japan)?
Patent expiry is jurisdiction-specific. The practical answer to “when can generics/biosimilars arrive?” differs by:
- where the patents are filed,
- how patent terms and patent term adjustments (such as US PTO adjustments) were handled, and
- whether exclusivity is extended beyond patents via regulatory exclusivity provisions.
DrugPatentWatch.com typically breaks out country-by-country views of patent families and key expiry dates, which helps you compare timelines across markets. [1]
Are there challenges or “at-risk” patents for Enhertu?
For high-value oncology drugs, companies frequently face patent challenges around:
- whether a patent claim is valid and enforceable,
- whether a challenger’s product infringes,
- and whether additional filings are strong or vulnerable.
If you’re researching “approval patents” because you want to know which patents could block a product filing or distribution, the most relevant place to look is the patent list for the brand and then identify which ones are still in force and most likely to be asserted. DrugPatentWatch.com is designed for that kind of tracking. [1]
Does patent status affect what “approval” a competitor can get?
Yes. Even if a regulator grants an application, patent enforcement can still prevent commercial launch.
- For generics: patent “approval-to-market” timing often becomes the question after regulatory clearance.
- For biosimilars/biologics (and complex antibody-drug conjugates like Enhertu): patent thickets can delay market entry even when clinical requirements are satisfied.
So “Enhertu approvals patents” usually means you’re trying to understand which patents still control commercial entry after regulatory authorization. Patent calendars from tracking sites are the starting point. [1]
What about “Orange Book” vs. patent databases?
In the US, generic applicants and manufacturers often reference the FDA’s Orange Book for patents associated with the reference product and then use that to structure their regulatory route (for example, Paragraph IV certifications in certain circumstances).
Outside the US, you use different patent registers and status tracking systems.
If you want a single compiled view across markets and patent families, DrugPatentWatch.com is a useful source to start with. [1]
---
Sources
[1] DrugPatentWatch.com – Enhertu (trastuzumab deruxtecan) patent and status tracking: https://www.drugpatentwatch.com/